BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

197 related articles for article (PubMed ID: 35472244)

  • 41. MLL-PTD in a 13-year-old patient with blast phase myeloproliferative neoplasm: A case report.
    He Z; Wang B; Chen L; Huang Y; Wang H; Yang M; Xiao X; Lu Y; Chen J; Wu Y
    Medicine (Baltimore); 2018 Nov; 97(46):e13220. PubMed ID: 30431598
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Myeloid neoplasm with eosinophilia and
    Salehi S; Astle JM; Sadigh S; Lake J; Aikawa V; Tang G; Wang SA; Bagg A
    Leuk Lymphoma; 2019 Sep; 60(9):2299-2303. PubMed ID: 30806106
    [No Abstract]   [Full Text] [Related]  

  • 43. Advances in understanding and management of myeloproliferative neoplasms.
    Vannucchi AM; Guglielmelli P; Tefferi A
    CA Cancer J Clin; 2009; 59(3):171-91. PubMed ID: 19369682
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Burkitt leukemia with precursor B-cell features that developed after ruxolitinib treatment in a patient with hydroxyurea-refractory JAK2
    Fukutsuka K; Iioka F; Maekawa F; Nakagawa M; Kishimori C; Hayashida M; Tagawa S; Akasaka T; Honjo G; Ohno H
    J Clin Exp Hematop; 2021 Jun; 61(2):114-119. PubMed ID: 33994432
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Simultaneous screening for JAK2 and calreticulin gene mutations in myeloproliferative neoplasms with high resolution melting.
    Matsumoto N; Mori S; Hasegawa H; Sasaki D; Mori H; Tsuruda K; Imanishi D; Imaizumi Y; Hata T; Kaku N; Kosai K; Uno N; Miyazaki Y; Yanagihara K
    Clin Chim Acta; 2016 Nov; 462():166-173. PubMed ID: 27693531
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Isolated del(5q) in myeloid malignancies: clinicopathologic and molecular features in 143 consecutive patients.
    Patnaik MM; Lasho TL; Finke CM; Knudson RA; Ketterling RP; Chen D; Hoyer JD; Hanson CA; Tefferi A
    Am J Hematol; 2011 May; 86(5):393-8. PubMed ID: 21523797
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Acute myeloid leukemia following a myeloproliferative neoplasm: clinical characteristics, genetic features and effects of therapy.
    Heaney ML; Soriano G
    Curr Hematol Malig Rep; 2013 Jun; 8(2):116-22. PubMed ID: 23572311
    [TBL] [Abstract][Full Text] [Related]  

  • 48. [Regulation of Ruxolitinib on matrix metalloproteinase in JAK2V617F positive myeloroliferative neoplasms cells].
    Liu GM; Zhang LJ; Fu JZ; Liang WT; Cheng ZY; Bai P; Bian YS; Wan JS
    Zhonghua Xue Ye Xue Za Zhi; 2017 Feb; 38(2):140-145. PubMed ID: 28279039
    [No Abstract]   [Full Text] [Related]  

  • 49. Efficacy of ruxolitinib in myeloid neoplasms with PCM1-JAK2 fusion gene.
    Rumi E; Milosevic JD; Selleslag D; Casetti I; Lierman E; Pietra D; Cavalloni C; Bellini M; Milanesi C; Dambruoso I; Astori C; Kralovics R; Vandenberghe P; Cazzola M
    Ann Hematol; 2015 Nov; 94(11):1927-8. PubMed ID: 26202607
    [No Abstract]   [Full Text] [Related]  

  • 50. Clinical outcomes of myeloid/lymphoid neoplasms with fibroblast growth factor receptor-1 (FGFR1) rearrangement.
    Umino K; Fujiwara SI; Ikeda T; Toda Y; Ito S; Mashima K; Minakata D; Nakano H; Yamasaki R; Kawasaki Y; Sugimoto M; Yamamoto C; Ashizawa M; Hatano K; Sato K; Oh I; Ohmine K; Muroi K; Kanda Y
    Hematology; 2018 Sep; 23(8):470-477. PubMed ID: 29486661
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Mutational landscape of blast phase myeloproliferative neoplasms (MPN-BP) and antecedent MPN.
    Pasca S; Chifotides HT; Verstovsek S; Bose P
    Int Rev Cell Mol Biol; 2022; 366():83-124. PubMed ID: 35153007
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Molecular genetics of BCR-ABL1 negative myeloproliferative neoplasms in India.
    Rabade N; Subramanian PG; Kodgule R; Raval G; Joshi S; Chaudhary S; Mascarenhas R; Tembhare P; Gujral S; Patkar N
    Indian J Pathol Microbiol; 2018; 61(2):209-213. PubMed ID: 29676359
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Clinical and histopathological features of myeloid neoplasms with concurrent Janus kinase 2 (JAK2) V617F and KIT proto-oncogene, receptor tyrosine kinase (KIT) D816V mutations.
    Naumann N; Lübke J; Shomali W; Reiter L; Horny HP; Jawhar M; Dangelo V; Fabarius A; Metzgeroth G; Kreil S; Sotlar K; Oni C; Harrison C; Hofmann WK; Cross NCP; Valent P; Radia D; Gotlib J; Reiter A; Schwaab J
    Br J Haematol; 2021 Jul; 194(2):344-354. PubMed ID: 34060083
    [TBL] [Abstract][Full Text] [Related]  

  • 54. [Novel method in diagnosis of chronic myeloproliferative disorders--detection of JAK2 mutation].
    Rajnai H; Bödör C; Reiniger L; Timár B; Csernus B; Szepesi A; Csomor J; Matolcsy A
    Orv Hetil; 2006 Nov; 147(45):2175-9. PubMed ID: 17402211
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Identification of RNPC3 as a novel JAK2 fusion partner gene in B-acute lymphoblastic leukemia refractory to combination therapy including ruxolitinib.
    Chen X; Wang F; Zhang Y; Ma X; Liu M; Cao P; Zhou L; Wang L; Zhang X; Wang T; Liu H
    Mol Genet Genomic Med; 2020 Mar; 8(3):e1110. PubMed ID: 31885183
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Underlying mechanisms of the JAK2V617F mutation in the pathogenesis of myeloproliferative neoplasms.
    Mullally A
    Pathologe; 2016 Nov; 37(Suppl 2):175-179. PubMed ID: 27796499
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Coexistence of JAK2 or CALR mutation is a rare but clinically important event in chronic myeloid leukemia patients treated with tyrosine kinase inhibitors.
    Lewandowski K; Gniot M; Wojtaszewska M; Kanduła Z; Becht R; Paczkowska E; Mędraś E; Wasilewska E; Iwoła M
    Int J Lab Hematol; 2018 Jun; 40(3):366-371. PubMed ID: 29508552
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Molecular characterization of chronic myeloproliferative neoplasias in México.
    Ruiz-Argüelles GJ; Garcés-Eisele J; Ortiz-López R; Rivas-Llamas R; Gómez-Almaguer D; Ruiz-Delgado GJ
    Hematology; 2009 Oct; 14(5):261-5. PubMed ID: 19843380
    [TBL] [Abstract][Full Text] [Related]  

  • 59. JAK and MPL mutations in myeloid malignancies.
    Tefferi A
    Leuk Lymphoma; 2008 Mar; 49(3):388-97. PubMed ID: 18297515
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Clinical Implications of Quantitative JAK2 V617F Analysis using Droplet Digital PCR in Myeloproliferative Neoplasms.
    Lee E; Lee KJ; Park H; Chung JY; Lee MN; Chang MH; Yoo J; Lee H; Kong SY; Eom HS
    Ann Lab Med; 2018 Mar; 38(2):147-154. PubMed ID: 29214759
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.